Global Gastrointestinal Diseases Drug Development Market - Industry Trends and Forecast to 2028

  • Pharmaceutical
  • Upcoming Report
  • Jul 2021
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Gastrointestinal Diseases Drug Development Market, By Disease Type (Gastroenteritis, Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome and Others), Molecular targets (Sodium Transporter NHE3 Inhibitor, Sphinogosine-1-Phosphate Receptor Functional Antagonist, Tumor Necrosis Factor (TNF) Blocker and Others), Marketed Drugs (Infliximab, Adalimumab, Mesalazine and Others), Clinical Trials (Etrolizumab, SHP647, ABX464, ASP3291 and Others), Route of Administration (Oral and Injectable), End Users (Hospitals, Homecare, Specialty Clinics and Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.

Gastrointestinal Diseases Drug Development Market Market Analysis and Insights of Gastrointestinal Diseases Drug Development Market

Data Bridge Market Research analyses that the gastrointestinal diseases drug development will exhibit a CAGR of around 6.90% for the forecast period of 2021-2028. Rising expenditure for the research and development activities by the pharmaceutical companies to develop a strong pipeline of drugs, increasing prevalence of gastrointestinal diseases across the globe, and increased expenditure for the development of healthcare infrastructure are the major factors attributable to the growth of gastrointestinal diseases drug development market.

From the name itself, it is clear that gastrointestinal diseases are the diseases related to the gastrointestinal tract. A few examples of gastrointestinal diseases are constipation, inflammatory bowel diseases, irritable bowel syndrome, colitis, and so on.

Growing focus on the biologics for the treatment of gastrointestinal diseases is a major factor fostering the growth of the market. Rising clinical trial activities by the pharmaceutical companies and ever-rising geriatric population are other factors also fostering the development of the market. Unhealthy eating habits and increasing personal disposable income are some other indirect determinants that will create lucrative market growth opportunities.

However, patent expiry of several dugs will pose a major challenge to the market growth. Huge expenditure involved in research and development activities will further challenge the market growth rate. Risk factors related to behavioral, psychosocial, and socio-environmental aspects will further derail the market growth rate.

This gastrointestinal diseases drug development market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on gastrointestinal diseases drug development market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Gastrointestinal Diseases Drug Development Market Scope and Market Size

The gastrointestinal diseases drug development market is segmented on the basis of disease type, molecular targets, marketed drugs, clinical trials, route of administration, and end users. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with a valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

  • On the basis of disease type, the gastrointestinal diseases drug development market is segmented into gastroenteritis, inflammatory bowel disease (IBD), irritable bowel syndrome, and others.
  • On the basis of molecular targets, the gastrointestinal diseases drug development market is segmented into sodium transporter NHE3 inhibitor, sphinogosine-1-phosphate receptor functional antagonist, tumor necrosis factor (TNF) blocker, and others.
  • On the basis of marketed drugs, the gastrointestinal diseases drug development market is segmented into infliximab, adalimumab, mesalazine and others.
  • On the basis of clinical trials, the gastrointestinal diseases drug development market is segmented into etrolizumab, SHP647, ABX464, ASP3291, and others.
  • On the basis of route of administration, the gastrointestinal diseases drug development market is segmented into oral and injectable.
  • On the basis of end users, the gastrointestinal diseases drug development market is segmented into hospitals, homecare, specialty clinics, and others.

Gastrointestinal Diseases Drug Development Market Country Level Analysis

The gastrointestinal diseases drug development market is analysed and market size insights and trends are provided by country, disease type, molecular targets, marketed drugs, clinical trials, route of administration, and end users as referenced above.

The countries covered in the gastrointestinal diseases drug development market report are U.S., Canada, and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America dominates the gastrointestinal diseases drug development market owing to the growing research and development activities. Asia-Pacific is projected to score highest growth rate and exhibit the highest CAGR for the forecast period. This is because of the rise in geriatric population.

The country section of the gastrointestinal diseases drug development market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The gastrointestinal diseases drug development market also provides you with detailed market analysis for patient analysis, prognosis, and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Gastrointestinal Diseases Drug Development Market Share Analysis

The gastrointestinal diseases drug development market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to gastrointestinal diseases drug development market.

The major players covered in the gastrointestinal diseases drug development market report are F. Hoffmann-La Roche Ltd, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited., GlaxoSmithKline plc, Abbott, Kyowa Kirin Co., Ltd., Mitsubishi Tanabe Pharma Corporation., Ardelyx, RedHill Biopharma Ltd., Shanghai Fosun Pharmaceutical(Group)Co., Ltd., Avexegen Therapeutics, Inc., Knight Therapeutics Inc., Daewon Pharmaceutical Co., Ltd., Metacrine, Vaxart, Inc., SynAct Pharma AB, Sequella, Inc., Liminal BioSciences Inc., and SHIELD THERAPEUTICS. among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Customization Available : Global Gastrointestinal Diseases Drug Development Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions